ANI Pharmaceuticals (ANIP) 8-K Other Events

Exhibit 99.1

BIOSANTE PHARMACEUTICALS, INC.

SELECTED FINANCIAL DATA

	Year Ended December 31,															Three Months Ended March 31,
	2011			2010			2009			2008			2007			2012			2011
	(in thousands, except per share data)
Statement of Operations Data:
Revenue	$	435		$	2,474		$	1,258		$	3,781		$	493		$	114		$	57
Expenses
Research and development	44,182			39,706			13,681			15,790			4,751			5,183			14,864
General and administration	6,982			5,940			5,374			5,125			4,331			1,832			1,594
Acquired in-process research and development	—			—			9,000			—			—			—			—
Excess consideration paid over fair value	—			—			20,192			—			—			—			—
Licensing expense	50			269			300			836			—			—			—
Depreciation and amortization	148			168			137			43			90			31			42
Total expenses	51,362			46,083			48,684			21,794			9,172			7,046			16,500
Other (expense) income — Convertible note fair value adjustment	(23		)	(1,871		)	33			—			—			(3,210		)	(639		)
Other expense — Investment impairment charge	—			(286		)	—			—			—			—			—
Other interest (expense) income	(673		)	(675		)	(135		)	588			1,095			(124		)	(172		)
Other income	15			245			—			—			—			2			3
Net loss	$	(51,608	)	$	(46,196	)	$	(47,528	)	$	(17,425	)	$	(7,584	)	$	(10,264	)	$	(17,251	)
Basic and diluted net loss per common share*	$	(3.15	)	$	(4.21	)	$	(8.40	)	$	(3.83	)	$	(1.79	)	$	(0.53	)	$	(1.22	)
Weighted average number of common shares and common equivalent shares outstanding*	16,398			10,985			5,659			4,551			4,248			19,378			14,127

	As of December 31,										As of March 31,
	2011		2010		2009		2008		2007		2012		2011
	(in thousands)
Balance Sheet Data:
Cash, cash equivalents and short-term investments	$	57,225	$	38,155	$	29,858	$	14,787	$	30,655	$	49,474	$	51,349
Total assets	62,380		44,767		36,437		17,679		31,241		54,575		56,805
Total current liabilities (includes short-term convertible senior notes in 2010)	7,228		8,183		3,930		3,853		1,516		6,085		12,633
Convertible senior notes, total long-term	17,337		17,436		16,676		—		—		10,494		18,037
Stockholders’ equity	37,815		19,147		15,830		13,826		29,725		37,996		26,136

*All share and per share numbers have been adjusted retroactively to reflect the one-for-six reverse stock split effected on June 1, 2012.